试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-18
Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant
编号:NCT02846376登记状态:提前终止企业 / 申办者:Hackensack Meridian Health
药物 / 成分:Nivolumab、Ipilimumab
登记的停止原因(原文):Lack of Enrollment
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-18
Intranasal Ketamine for Pain Control in Patients with Sickle Cell Disease and Vaso-occlusive Episode (VOE) in the PED
编号:NCT04150757登记状态:提前终止企业 / 申办者:Abigail Nixon
药物 / 成分:Intranasal ketamine
登记的停止原因(原文):Poor recruitment secondary to COVID
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-18
IBI310 in Combination with Sintilimab in Patients with DNA Mismatch Repair Deficient (dMMR)/microsatellite Instability High (MSI-H) Locally-advanced or Metastatic Colorectal Cancer
编号:NCT04258111登记状态:提前终止企业 / 申办者:Innovent Biologics (Suzhou) Co. Ltd.
药物 / 成分:IBI310 (anti-CTLA-4 antibody)、Sintilimab(anti-PD-1 antibody)
登记的停止原因(原文):After careful consideration, our company has decided to revise the overall development strategy for IBI310 and discontinue further registration research for this project. Consequently, the ongoing screening process will be terminated, and this decisi
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-18
Cromolyn Sodium for Treatment of COVID-19 Pneumonia
编号:NCT05077917登记状态:提前终止企业 / 申办者:Texas Tech University Health Sciences Center, El Paso
药物 / 成分:Cromolyn Sodium、Placebo
登记的停止原因(原文):slow enrollment
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-18
Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors
编号:NCT05228015登记状态:提前终止企业 / 申办者:Ikena Oncology
药物 / 成分:IK-930、Osimertinib
登记的停止原因(原文):Sponsor strategic reasons
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-18
A Study Investigating Lu AG06474 in Healthy Young Participants
编号:NCT05943327登记状态:提前终止企业 / 申办者:H. Lundbeck A/S
药物 / 成分:Lu AG06474、Placebo、Lu AG06474
登记的停止原因(原文):For strategic reasons
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-15
Step-up to Medium Strength Triple Therapy vs High Strength ICS/LABA in Adult Asthmatics Uncontrolled on Medium Strength ICS/LABA
编号:NCT05018598登记状态:提前终止企业 / 申办者:Chiesi Farmaceutici S.p.A.
药物 / 成分:Administration via pressurized metered dose inhaler (pMDI)、Administration via pressurized metered dose inhaler (pMDI)
登记的停止原因(原文):The study was prematurely stopped due to extensive challenges in patient recruitment. The Sponsor issued a notification of early study termination to all investigational sites and all external stakeholders.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-15
A Drug-Drug Interaction Study to Estimate the Effect of PF-07081532 on the Pharmacokinetics of Dabigatran and Rosuvastatin in Overweight or Obese Adult Participants
编号:NCT05788328登记状态:提前终止企业 / 申办者:Pfizer
药物 / 成分:Dabigatran etexilate (DE)、Rosuvastatin、PF-07081532
登记的停止原因(原文):The decision to terminate clinical development of lotiglipron is based on pharmacokinetic data from Phase 1 drug-drug-interaction studies and laboratory measurements of elevated transaminases in these Phase 1 studies as well as a Phase 2 study.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-14
An Open Study of ASP8273 in Patients With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations
编号:NCT02192697登记状态:提前终止企业 / 申办者:Astellas Pharma Inc
药物 / 成分:ASP8273
登记的停止原因(原文):Following recommendation by SOLAR Study IDMC, Astellas closed enrollment in ASP8273 studies.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-14
Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)
编号:NCT03769467登记状态:提前终止企业 / 申办者:Atara Biotherapeutics
药物 / 成分:Tabelecleucel、Pembrolizumab
登记的停止原因(原文):Phase 1B part was completed with review of DLTs and cumulative safety data by Safety Data Review Committee and identification of a safe RP2D. Post-internal review, sponsor decided to terminate the study, and hence, Phase 2 part was not conducted.
查看官方原始记录 ↗